ICT-107

BIOLOGICAL2 trials

Sponsors

Precision Life Sciences Group

Conditions

Glioblastoma Multiforme

Phase 2

A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)

CompletedNCT01280552

Precision Life Sciences GroupGlioblastoma Multiforme

Start: 2011-01-31End: 2015-12-31Updated: 2017-03-20

Phase 3

Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma

SuspendedNCT02546102

Precision Life Sciences GroupGlioblastoma Multiforme

Start: 2024-12-31End: 2025-12-31Target: 234Updated: 2024-04-03

Related Papers

Comparative impact of treatment on clinical benefit in patients with glioblastoma (GBM) enrolled in the phase II trial of ICT-107.

Journal of Clinical Oncology2015-05-202 citations